Lonza and California Peptide Research Form Strategic Alliance

November 18,2010 Basel, Switzerland and Napa, California, USA

Lonza and California Peptide Research, Inc. (CPRI) have entered into a strategic collaboration to more effectively serve customers requesting peptide manufacturing and development services.

CPRI’s high-quality small-scale services complement Lonza's extensive capabilities in custom cGMP peptide manufacturing and development. With proximity to a core customer base in the North American pharmaceutical market, CPRI adds geographic diversity to Lonza's existing facilities in Braine-l'Alleud (Belgium), Visp (Switzerland), Nansha (China), and Kouřim (Czech Republic). CPRI’s offering includes milligram- to multi-gram-scale custom synthesis and a wide variety of catalogue products, as well as consulting services and technical support.

The alliance will provide customers a more complete peptide offering – from research through commercial supply – and enable a seamless transition of custom peptide projects between CPRI’s small-scale facility and Lonza’s cGMP facilities. Joint customers will benefit from aligned interfaces and more efficient technology transfer, thereby saving time and costs.

CPRI was identified as a competent innovator and qualified as a Lonza-trusted partner following a diligent selection and auditing process.

 

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, the company had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.

 

About California Peptide Research

California Peptide Research, Inc. (CPRI) provides high purity custom and catalog peptides. CPRI is a global manufacturing partner and supplier of reagents to leading life science organizations, government agencies and research professionals that require a wide variety of capabilities and service offerings. CPRI is located in Napa, California and was founded in 1993. Further information can be found at www.californiapeptide.com

 

For further information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

CPRI
President
Fabio Simi
Tel +1 (707) 224-8675
Fax +1 (707) 224-8678
fabio@californiapeptide.com

Browse All News
Bg